ANXA1 Protein Shields Kidneys From Diabetes Damage via Mitochondrial Pathway
Scientists uncover how ANXA1 activates UCP1 to preserve mitochondrial health in diabetic kidneys, revealing a promising new therapeutic target.
Summary
Researchers at Peking University identified a molecular chain of events by which the protein ANXA1 protects kidney cells from diabetic damage. ANXA1 stabilizes the transcription factor GATA3, which boosts expression of uncoupling protein 1 (UCP1). UCP1 in turn activates CRLS1 via ARX, driving cardiolipin production and reducing harmful mitochondrial fragmentation. In diabetic mouse models and human kidney cells, disrupting this pathway worsened kidney injury, while pharmacologically boosting UCP1 with CL316243 reversed established diabetic nephropathy. The findings pinpoint UCP1 as a central therapeutic target for a condition affecting hundreds of millions worldwide.
Detailed Summary
Diabetic nephropathy (DN) is one of the leading causes of chronic kidney disease globally, yet effective disease-modifying treatments remain limited. Mitochondrial dysfunction in kidney tubular cells is increasingly recognized as a driver of DN progression, making mitochondrial pathways attractive therapeutic targets.
This study builds on prior work showing that annexin A1 (ANXA1) protects against DN by improving mitochondrial homeostasis. Investigators used transcriptomics to identify uncoupling protein 1 (UCP1) as the most significantly downregulated mitochondria-associated gene in diabetic ANXA1-knockout mice. Using a suite of genetic models — including Anxa1/Ucp1 double-knockout mice and kidney-specific Ucp1/Crls1-overexpressing mice — alongside high-fat diet plus streptozotocin and db/db diabetic models, they systematically dissected the pathway.
Key results showed that ANXA1 stabilizes the transcription factor GATA3 in proximal tubular epithelial cells under high-glucose conditions. GATA3 binds the UCP1 promoter, enhancing its transcription. UCP1 then upregulates cardiolipin synthase 1 (CRLS1) through the transcription factor ARX, promoting cardiolipin biosynthesis. Cardiolipin is critical for inner mitochondrial membrane integrity; its depletion triggers excessive mitochondrial fission, inflammation, and fibrosis. Restoring UCP1 or CRLS1 reversed these defects and reduced albuminuria. Pharmacological UCP1 activation with CL316243 attenuated established DN in db/db mice.
These findings establish a coherent ANXA1 → GATA3 → UCP1 → ARX/CRLS1 → cardiolipin axis that governs mitochondrial fission in diabetic kidneys. Therapeutically, this positions UCP1 as an actionable drug target.
Caveats include reliance on animal and cell models; whether CL316243 or analogous UCP1 activators are safe and effective in humans with DN requires clinical investigation. UCP1 is classically associated with brown adipose tissue thermogenesis, so renal-specific targeting strategies will be important.
Key Findings
- ANXA1 stabilizes GATA3, which transcriptionally upregulates UCP1 in diabetic kidney tubular cells.
- UCP1 deficiency depleted renal cardiolipin and worsened albuminuria, fibrosis, and mitochondrial fission in diabetic mice.
- UCP1 promotes cardiolipin biosynthesis via the ARX/CRLS1 axis, preserving mitochondrial membrane integrity.
- Pharmacological UCP1 activation with CL316243 reversed established diabetic nephropathy in db/db mice.
- UCP1 was significantly upregulated in kidneys of both DN patients and diabetic mice, suggesting a compensatory protective role.
Methodology
The study used Anxa1-KO, Ucp1-KO, and double-KO mouse models alongside kidney-specific Ucp1/Crls1 overexpression in HFD/STZ and db/db diabetic models. In vitro work employed UCP1 knockdown and overexpression in proximal tubular epithelial cells (HK-2) under high-glucose conditions, supported by transcriptomics, metabolomics, and lipidomics.
Study Limitations
Findings are primarily from rodent models and cultured cells; human clinical validation is absent. UCP1 is canonically a brown adipose thermogenic protein, raising questions about renal specificity and off-target systemic effects of UCP1-activating drugs.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.